|
JP2008120809A
|
|
Therapeutic agent comprising wilms' tumor gene (wt1) expression inhibitor for solid tumor
|
|
US2010292160A1
|
|
HLA-A* 3303-restricted WT1 peptide and pharmaceutical composition comprising the same
|
|
JP2006267124A
|
|
Method for examining wt1-related disease
|
|
EP1738771A1
|
|
siRNA CAPABLE OF INHIBITING EXPRESSION OF WT1 GENE AND USE THEREOF
|
|
WO2005093076A1
|
|
Method of separating precusror cells of liver cells, endothelial cells or hematopoietic cells from cell mass
|
|
EP1738772A1
|
|
Micro rna inhibiting the expression of wt1 gene and utilization of the same
|
|
WO2004026897A1
|
|
Wt1 substitution peptides
|
|
AU2003262094A1
|
|
Cancer antigen peptide preparation
|
|
WO03106682A1
|
|
Hla-a24-restricted cancer antigen peptide
|
|
WO03028758A1
|
|
Novel method of inducing antigen-specific t cells
|
|
US8735357B2
|
|
Method of inducing antigen-specific T cells
|
|
AU2710101A
|
|
Wt1-interacting protein wtip
|
|
JP2002048793A
|
|
Examination method of wt1-related disease
|
|
JPH1189599A
|
|
Quantitative determination of expression of human wt1 by corrected competitive pt-pcr method
|
|
JPH1135484A
|
|
Therapeutic agent for solid tumor containing expression inhibitor against wilms tumor gene (wt1)
|
